Cadrenal adds VLX-1005 to anticoagulation pipeline

Cadrenal Therapeutics (NASDAQ: CVKD) announced the acquisition of VLX-1005, a Phase 2 drug candidate for Heparin-Induced Thrombocytopenia (HIT) with Orphan Drug and Fast Track designations from the Food and Drug Administration.

The company now operates three clinical-stage assets in the anticoagulation market. VLX-1005 is a 12-LOX inhibitor designed to treat HIT, a dangerous hospital complication with limited treatment options. The acquisition adds to Cadrenal's existing pipeline, which includes tecarfarin for chronic anticoagulation in kidney disease patients and frunexian, a Factor XIa antagonist for acute hospital settings.

Tecarfarin targets patients with end-stage kidney disease and atrial fibrillation who face challenges with current anticoagulants including warfarin and direct oral anticoagulants. The drug candidate is approaching Phase 3 trial readiness, according to the company's statement.

The Factor XIa portfolio positions Cadrenal in acute hospital environments where controlled anticoagulation is needed. Combined with tecarfarin's chronic-care applications, the company now addresses multiple treatment settings within anticoagulation therapy.

Cadrenal reported advancing manufacturing readiness and adding clinical expertise to its leadership team since August. The company operates in what it describes as a $40 billion anticoagulation market.

HIT occurs when patients develop antibodies against heparin, a commonly used blood thinner in hospitals. The condition can lead to dangerous blood clots and requires alternative anticoagulation approaches.

The information is based on a company press release statement. Cadrenal Therapeutics develops anticoagulation products for rare and high-risk patient populations who face limitations with existing therapies.

You May Also Be Interested In

• Electra Therapeutics files for proposed IPO
• Target registers 15.5 million additional shares for employee incentive plan
• McCormick board member to resign after CFO appointment at Best Buy